









Markets
/
Stocks
/
nasdaq-mygn
/

Myriad Genetics Inc

MYGN

5.120USD

+0.020+0.39%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

476.67MMarket Cap

LossP/E TTM



Myriad Genetics Inc

5.120

+0.020+0.39%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Myriad Genetics Inc

Currency: USD Updated: 2026-02-06

Key Insights

Myriad Genetics Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 76 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 7.70.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Myriad Genetics Inc's Score

Industry at a Glance

Industry Ranking

76 / 205

Overall Ranking

209 / 4521

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Myriad Genetics Inc Highlights

StrengthsRisks

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 23.47% year-on-year.

Overvalued

The company’s latest PE is -1.18, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 92.66M shares, decreasing 12.37% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 31.35K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.07.

Analyst Rating

Based on 13 analysts

Hold

Current Rating

7.700

Target Price

+45.28%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Myriad Genetics Inc is 7.02, ranking 110 out of 205 in the Healthcare Equipment & Supplies industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 205.70M, representing a year-over-year decrease of 3.56%, while its net profit experienced a year-over-year decrease of 23.98%.

Score

Industry at a Glance

Previous score

7.02

Change



Financials

7.80

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

5.82

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

8.56

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.77

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.14

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Myriad Genetics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Myriad Genetics Inc is 7.90, ranking 53 out of 205 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -1.18, which is -24.26% below the recent high of -0.89 and -1727.21% above the recent low of -21.52.

Score

Industry at a Glance

Previous score

7.90

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 76/205

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Myriad Genetics Inc is 5.85, ranking 181 out of 205 in the Healthcare Equipment & Supplies industry. The average price target is 8.00, with a high of 18.00 and a low of 3.50.

Score

Industry at a Glance

Previous score

5.85

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 13 analysts

Hold

Current Rating

7.700

Target Price

+45.28%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

114

Total

Median

Average

Company name

Ratings

Analysts

Myriad Genetics Inc

MYGN

Stryker Corp

SYK

Medtronic PLC

MDT

Dexcom Inc

DXCM

Abbott Laboratories

ABT

Zimmer Biomet Holdings Inc

ZBH

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Myriad Genetics Inc is 6.19, ranking 161 out of 205 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 6.51 and the support level at 4.37, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.16

Change

0.03

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.096

Sell

RSI(14)

27.994

Sell

STOCH(KDJ)(9,3,3)

11.227

Oversold

ATR(14)

0.304

Low Volatility

CCI(14)

-142.959

Sell

Williams %R

90.351

Oversold

TRIX(12,20)

-0.779

Sell

StochRSI(14)

13.420

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

5.266

Sell

MA10

5.494

Sell

MA20

5.790

Sell

MA50

6.440

Sell

MA100

6.954

Sell

MA200

6.186

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Myriad Genetics Inc is 10.00, ranking 1 out of 205 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 99.41%, representing a quarter-over-quarter increase of 0.73%. The largest institutional shareholder is The Vanguard, holding a total of 8.12M shares, representing 8.71% of shares outstanding, with 24.40% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

13.25M

-1.32%

The Vanguard Group, Inc.

Star Investors

7.77M

-15.03%

State Street Investment Management (US)

4.98M

+3.46%

Glenview Capital Management, LLC

Star Investors

4.59M

Millennium Management LLC

4.75M

-3.58%

D. E. Shaw & Co., L.P.

4.56M

+1.06%

Morgan Stanley & Co. LLC

2.49M

-26.17%

Jacobs Levy Equity Management, Inc.

2.44M

+157.01%

Geode Capital Management, L.L.C.

2.23M

+0.10%

Camber Capital Management LP

2.00M

-14.89%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Myriad Genetics Inc is 4.82, ranking 96 out of 205 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.90. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.